In all sample cohorts, GNB4 combined with Riplet had an AUC of 92.51% for any-stage HCC detection, which was higher than that for any single gene (GNB4:88.62%; Riplet:81.38%) (Figure 7i). This evidence concerns the gene GNB4 and hepatocellular carcinoma.